APEIRON Biologics commences clinical COVID-19 trial with inhaled APN01
Inhalation of APN01 to directly target SARS-CoV-2 virus in respiratory tract, the lung and tissue itself Primary objective is to evaluate safety and tolerability of inhaled APN01 Phase 1 trial to enroll about 40 healthy volunteers Additional US Phase 2 trial with intravenous administration of APN01 Press release (EN) | Presseaussendung (DE)
October 12, 2021
No Comments
The Cancer Revolution
Despite recent advances in the treatment of cancer, the disease remains a leading cause of death by disease worldwide1. It is reported that one in two people will be diagnosed with cancer in their lifetime2, resulting in a stronger-than-ever drive for new efficacious therapies. Our growing knowledge of cancer enables us to develop new technologies...
September 3, 2021
No Comments
APEIRON’s „Three questions to“
Prof. Josef Penninger 1. Do you remember your first "encounter" with the ACE2 molecule ? I remember well, it was in the hallway of the Ontario Cancer Institute. My postdoc Mike Crackower had just cloned the second ACE, hence ACE2. That was around 1998/1999. 2. Which physiological role does ACE2 have within the RAAS ?...
August 25, 2021
No Comments
APEIRON’s „Three questions to“
Prof. Chris Oostenbrink 1. How can computational techniques allow to study the effects of mutations of SARS-CoV-2 ? Computational methods allow us to describe molecular interactions at a space and time resolution that is often unattainable experimentally. This means that we can zoom in at an atomic level to understand visualize, rationalize, and predict what...
July 15, 2021
No Comments
APEIRON Biologics launches next clinical trial with innovative cancer therapy APN401

Important development step for promising cell therapy Paradigm shift in cancer treatment: process developed by APEIRON uses immune system to treat solid tumors Innovative new manufacturing and treatment process enables outpatient treatment within one day from cell collection to reinfusion Phase Ib clinical trial evaluates immunological effects as well as safety and tolerability of APN401…

July 6, 2021
No Comments
APEIRON’s „Three questions to“
Prof. Ali Mirazimi, Karolinska Institutet, Department of Laboratory Medicine, Sweden 1. Given your background working with vaccines and contagious viruses, what surprised you most when the new coronavirus struck in March 2020 ? Most surprising was the broad arsenal of disease complexity and how the virus could very quickly cause a pandemic disease with huge...
June 14, 2021
No Comments
APEIRON Biologics Announces Changes to Management and Supervisory Boards

Management Board to be expanded by Romana Gugenberger, PhD, as Chief Medical & Scientific Officer (CMSO) and Andreas Gerber, PhD, as Chief Operating Officer (COO) Prof. Josef Penninger moves from the Supervisory Board to the newly created Scientific Advisory Board, which he will build up and lead as Chairman Additional pre-clinical data show highly promising…

June 1, 2021
No Comments
ACE2 – locking the door against coronaviruses?
Over a year after its emergence, COVID-19 continues to remain a global plague. Even with the development of vaccines, we see the pandemic caused by SARS-CoV-2 to stay with us for a while. With the identification of major new virus variants of concern hailing from the United Kingdom, South Africa, and Brazil with improved binding...
May 27, 2021
No Comments